Trigeminal nerve endings (CN V endings)

The trigeminal nerve endings are the peripheral sensory terminals of the fifth cranial nerve (CN V), which provide sensory innervation to the face, scalp, and oral cavity [1.1.1, 1.4.3]. These endings are rich in nociceptors and express various ion channels and receptors, such as NaV1.7, NaV1.6, and TRPV1, which are essential for detecting and transmitting pain signals [1.2.1, 1.2.2]. In conditions like trigeminal neuralgia and migraine, these endings become hypersensitized due to factors like neurovascular compression or inflammatory mediators, leading to severe, paroxysmal pain [1.1.4, 1.2.3]. While the nerve endings are an anatomical structure rather than a single molecular target, they are the site of action for numerous therapies, including local anesthetics, botulinum toxin, and CGRP-targeted drugs [1.1.3, 1.4.1]. Modulating the activity of these endings is a primary strategy for managing chronic orofacial pain and primary headache disorders [1.2.5, 1.4.5]. Therapeutic interventions often aim to stabilize neuronal membranes or inhibit the release of vasoactive neuropeptides from these terminals [1.2.1, 1.4.1]. Consequently, they represent a critical anatomical focus for both pharmacological and surgical pain management strategies [1.1.5, 1.4.2].

Other names

Trigeminal nerve terminalsCranial nerve V endingsTrigeminal sensory fibersPeripheral trigeminal terminals

Drugs targeting the trigeminal nerve endings primarily act by inhibiting voltage-gated sodium channels (e.g., NaV1.6, NaV1.7) to stabilize hyperexcited neuronal membranes, blocking the release of neuropeptides like CGRP and Substance P, or desensitizing nociceptive receptors such as TRPV1 [1.2.1, 1.4.1, 1.4.3].